Gateway Investment Advisers’s Madrigal Pharmaceuticals MDGL Stock Holding History

Gateway Investment Advisers’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$278K	Buy	+518	New	+$265K	﹤0.01%	721

Other funds holding MDGL

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

EAM

EULAV Asset Management Sarasota, Florida $3.13B AUM 23.04% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Waterloo Capital Austin, Texas $1.78B AUM 27.25% 1-Year Est. Return

Gateway Investment Advisers's MDGL Position: Q2 2026 in Review

Gateway Investment Advisers opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 518 shares worth $278K. The stake represents ﹤0.01% of the portfolio and ranks #721 among its holdings.

105 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Gateway Investment Advisers held 518 shares of Madrigal Pharmaceuticals worth $278K as of Q2 2026.
Madrigal Pharmaceuticals was a new Gateway Investment Advisers position in Q2 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of Gateway Investment Advisers's portfolio in Q2 2026, its #721 holding.
105 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Gateway Investment Advisers's 13F filing for Q2 2026, filed 20 Jul 2026.